Milestones
Milestones
1923 Privately founded as Mustafa Nevzat Laboratory in Üsküdar/Ýstanbul by Prof. Mustafa Nevzat Pýsak who played a great role in establishing contemporary pharmacy in Turkey.
1930 Production of Pavotin ampoule containing opium alkaloids extracted from poppy seed.
1933 Mustafa Nevzat Laboratory, first moved to Divanyolu, then to Nuruosmaniye which are located in the European part of Ýstanbul.
1935 An injectable product of powdered insulin was manufactured for the first time in Turkey.
1957 Moved to Mecidiyeköy/Ýstanbul and became a joint stock company.
1961 The first enteric-coated tablet was registered in Turkey (Entersal).
1968-1970 New buildings were added to the Production and Quality Control units.
1974 Start of the production of active pharmaceutical ingredients (API).
1977 Some pharmaceutical forms such as syrups, ointments, creams and dry powder suspensions were produced at the temporary building in Yenibosna/Ýstanbul.
1984 A dedicated production plant established in Yenibosna to manufacture finished dosage forms of penicillin-like beta-lactams (Plant I - Penicillin-like Beta-lactam Products).
1996 A dedicated production plant established in Yenibosna to manufacture finished dosage forms of cephalosporin-like beta-lactams (Plant II - Cephalosporin-like Beta-lactam Products).
2000 The API Units were moved from Ýzmit-Köseköy to the new modern facilities at Çayýrova-Þekerpýnar. In these modern facilities, Clarithromycin and Clarithromycin granules for suspension, Sulbactam Sodium, Sultamicillin Tosylate and Sultamicillin Base were produced in those years.
2003 Yenibosna Plant III, which is one of the most modern facilities in Turkey, was completed. This plant is dedicated to non-penicillin and non-cephalosporin finished dosage forms (Plant III - Other Products).
2005 MN Pharmaceuticals signed strategic partnership agreements with several leading US generic companies for marketing and sales of its products and has submitted the first ANDA dossier to FDA. This is also a “first” for the Turkish Pharmaceutical Industry. By taking the initial step in exporting finished dosage forms to US, MN Pharmaceuticals has paved the way for the other Turkish pharmaceutical companies to follow.
2006 The API and finished dosage forms facilities have been inspected and approved by FDA in November. As a result of FDA inspection, MN Pharmaceuticals has been the first Turkish Pharma Company which has been granted the FDA approval for the API and finished dosage forms.
2007 The finished dosage forms facilities have been awarded the Environment Management Systems Certificate in the scope of ISO 14001 Standards by the British Management Systems Organization BSI.

In May, the first export of finished dosage forms was performed from Turkey to USA.
2008 As a result of the MHRA inspection conducted in May, MN Pharmaceuticals received the Certificate of GMP Compliance of a Manufacturer from the British Ministry of Health.

The second product entered the USA market in July.
2009 The newly established and the fourth production plant of the finished dosage forms facilities, Injectable Oncolytic Products Plant was completed at the beginning of 2009.

Following the certification investigation studies conducted by Turkish Standards Institute, MN Pharmaceuticals Active Pharmaceutical Ingredients Plant has been awarded the Environment Management System Certificate in the scope of TSE ISO 14001 Standards in January.

The finished dosage forms facilities have been awarded the OHSAS 18001 Occupational Health and Safety Certificate which was presented by the British Management Systems Organization BSI.

The finished dosage forms facilities have been inspected and approved for the fourth time by German Health authorities and EU-GMP Certificate has been granted. (First approval was received in July, 2004.)
2010 2010 The Oncolytic Products Plant was approved by the US Food and Drug Administration (FDA) in May and by the European Medicine Agency (EMEA) in July.

In December, the oncolytic drugs were shipped from Turkey to USA for the first time.
2011 Plant I- Penicillin like Beta lactam Products, Plant II- Cephalosporin like Beta lactam Products and Plant III- Other Products were inspected and approved by the GCC ( Gulf Cooperation Council).
2012 As of 12.06.2012, 99.8 percent of MN Pharmaceuticals shares was acquired by Amgen.